Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 14/20 | 0.50 |
| ▸ | CCND1 | P24385 | 14/20 | 0.50 |
| ▸ | CCND2 | P30279 | 14/20 | 0.50 |
| ▸ | CCND3 | P30281 | 14/20 | 0.50 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.46 |
| ▸ | CDK1 | P06493 | 3/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10246368 | 0.90 | CDK4 (0.47) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL10192629 | 0.88 | CDK4 (0.48) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL10192624 | 0.86 | CDK4 (0.57) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL10246376 | 0.85 | CDK4 (0.49) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL10192632 | 0.83 | CDK4 (0.46) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL16286108 | 0.82 | TDP1 (0.41) | — | |
| SCHEMBL10192630 | 0.81 | CDK4 (0.47) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL10192701 | 0.81 | PAK3 (0.52) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL15034775 | 0.81 | CDK4 (0.46) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL15035005 | 0.79 | MAPK8 (0.47) | CDK4CCND1CCND2CCND3CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120270844-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270844-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | PSEN2, MAPT, PSEN1 | CDK4 2592/4885CCND1 4850/4885CCND2 4797/4885 |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | CDK4 2824/4885CCND1 4822/4885CCND2 4718/4885 |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | PAK2, PAK3, PAK4 | CDK4 2735/4885CCND1 4872/4885CCND2 4839/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | CDK4 1028/4885CCND1 4465/4885CCND2 4323/4885 |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | PAK2, PAK3, PAK4 | CDK4 2596/4885CCND1 4856/4885CCND2 4795/4885 |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | SMN1; SMN2, PYGB, PMP22 | CDK4 2822/4885CCND1 4884/4885CCND2 4879/4885 |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | CHAT, PSEN2, PAK2 | CDK4 2088/4885CCND1 4589/4885CCND2 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.